Peptides for Metabolism
The peptides people most often research for metabolism, with how much evidence exists for each. A long list does not mean any of them is proven to work in people.
- Peptides listed
- 4
- With human trials
- 3
- FDA approved (any use)
- 3
- TirzepatideGLP-1 / GIP dual agonistHuman RCT evidence, 4 of 4Diabetes, obesity & metabolism 2025, PMID 39996356Human85Animal19Summarised3FDA approved (Mounjaro, Zepbound)Overview
- SemaglutideGLP-1 agonistNo study with an outcome for metabolismPubMed search, 2 Oct 2026Human144Animal60Summarised0FDA approved (Ozempic, Wegovy, Rybelsus)Overview
- RetatrutideGLP-1 / GIP / glucagon triple agonistHuman RCT evidence, 4 of 4Lancet 2026, PMID 42250575Human6Animal4Summarised4Investigational · phase 3Overview
- HGHRecombinant growth hormoneHuman RCT evidence, 4 of 4The Journal of clinical endocrinology and metabolism 2003, PMID 12679422Human650Animal88Summarised3FDA approved (prescription only)Overview
What this list does not show
Search demand tells you what people are curious about, not what works. Read each peptide's evidence before anything else.
Search interest is not evidence
This list follows what people search for and discuss. It says nothing about how well any peptide works.Animal results may not carry over
Doses, routes and effects seen in rodents or cell dishes often have no tested human equivalent.Approval covers specific uses
An FDA approval applies to the conditions and doses on the label, not to every goal a drug is searched with.Combinations are a separate question
Blends and stacks put several peptides together. Evidence for one peptide is not evidence for the mix.What metabolism means
MedlinePlus defines metabolism as the process the body uses to make energy from the food you eat.[15]
It adds that the body can use this fuel right away or store the energy in body tissues.[15]
What trials of the listed peptides measured
PubMed records matching the site's metabolism search: Tirzepatide 85 human-only and 19 animal-only; Semaglutide 144 human-only and 60 animal-only; Retatrutide 6 human-only and 4 animal-only; growth hormone 650 human-only and 88 animal-only.
Calculated from goal metabolism; ledger date 2026-10-02; counts tirzepatide (human only 85, animal 19, rct 13), semaglutide (human only 144, animal 60, rct 18), retatrutide (human only 6, animal 4, rct 1), hgh (human only 650, animal 88, rct 159). Formula: Copied from web/src/data/goals.json: peptides[].ledger.humanOnly.n and ledger.animal.n for this goal (PubMed title/abstract search, humans[mh] NOT animals vs animals NOT humans).
In a DXA substudy of SURMOUNT-1, tirzepatide cut body weight by 21.3%, fat mass by 33.9% and lean mass by 10.9% at week 72, versus 5.3%, 8.2% and 2.6% with placebo.[1]
A meta-analysis across the GLP-1 drug class found lean mass loss made up approximately 25% of total weight loss.[16]
Retatrutide lowered HbA1c by 2·02% at the 12 mg escalation dose versus 0·01% on placebo in people with type 2 diabetes at the primary endpoint.[17]
Growth hormone moved body composition in GH-deficient adults, with body fat down 10.89% and lean mass up 5.09% within 3 months of treatment.[18]
In a trial of growth hormone therapy, insulin-stimulated glucose uptake was impaired by 52% at 1 week and 39% at 6 months.[3]
What FDA labelling covers
The Wegovy label's indication is to reduce excess body weight and maintain weight reduction long term.[19]
Common questions
Can peptides speed up metabolism?
The outcomes cited here are body composition, HbA1c and glucose uptake; in the growth hormone trial, insulin-stimulated glucose uptake fell by 52% at 1 week and 39% at 6 months.[3]
Do GLP-1 peptides cause muscle loss?
In one pooled analysis, lean mass loss made up approximately 25% of total weight loss across the GLP-1 class.[16]
Which peptide improves blood sugar most in trials?
In a type 2 diabetes trial, retatrutide lowered HbA1c by 1·94% at 12 mg versus 0·81% on placebo.[2]
Explore nearby goals
Sources
- 1Body composition changes during weight reduction with tirzepatide in the SURMOUNT-1 study of adults with obesity or overweight.Diabetes, obesity & metabolism · 2025PMID 39996356Accessed 2 Oct 2026
- 2Efficacy and safety of retatrutide, a GIP, GLP-1, and glucagon receptor agonist, in people with type 2 diabetes and inadequate glycaemic control with diet and exercise (TRANSCEND-T2D-1): a double-blind, randomised, phase 3 trial.Lancet (London, England) · 2026PMID 42250575Accessed 2 Oct 2026
- 3Growth hormone replacement therapy induces insulin resistance by activating the glucose-fatty acid cycle.The Journal of clinical endocrinology and metabolism · 2003PMID 12679422Accessed 2 Oct 2026
- 4PubMed search: semaglutide[ti] AND (STEP OR "once-weekly semaglutide in adults with overweight or obesity" OR "Semaglutide 2.4 mg") AND randomized controlled trial[pt] (136 results)PubMed · 2026pubmed.ncbi.nlm.nih.govAccessed 2 Oct 2026
- 5PubMed search: semaglutide[ti] AND (cardiovascular outcomes OR "SELECT" OR "SUSTAIN" OR "PIONEER 6" OR "myocardial infarction") (560 results)PubMed · 2026pubmed.ncbi.nlm.nih.govAccessed 2 Oct 2026
- 6PubMed search: semaglutide[ti] AND (kidney OR FLOW OR "steatohepatitis" OR ESSENCE OR "heart failure" OR "knee osteoarthritis" OR Alzheimer) (590 results)PubMed · 2026pubmed.ncbi.nlm.nih.govAccessed 2 Oct 2026
- 7PubMed search: semaglutide[tiab] AND (meta-analysis[pt] OR systematic review[pt]) AND (weight OR obesity OR cardiovascular OR HbA1c) (361 results)PubMed · 2026pubmed.ncbi.nlm.nih.govAccessed 2 Oct 2026
- 8PubMed search: semaglutide[tiab] AND (pharmacokinetic*[tiab] OR half-life[tiab]) AND humans[mh] (136 results)PubMed · 2026pubmed.ncbi.nlm.nih.govAccessed 2 Oct 2026
- 9PubMed search: semaglutide[ti] AND (chronic kidney disease OR "knee osteoarthritis") AND randomized controlled trial[pt] (27 results)PubMed · 2026pubmed.ncbi.nlm.nih.govAccessed 2 Oct 2026
- 10PubMed search: semaglutide[tiab] AND (depress*[ti] OR suicid*[ti] OR "psychiatric"[ti] OR Alzheimer*[ti] OR cognit*[ti]) (159 results)PubMed · 2026pubmed.ncbi.nlm.nih.govAccessed 2 Oct 2026
- 11PubMed search: semaglutide[tiab] AND (blood pressure[ti] OR lipid*[ti] OR cholesterol[ti] OR "visceral"[ti] OR "waist"[ti] OR "body composition"[ti]) (112 results)PubMed · 2026pubmed.ncbi.nlm.nih.govAccessed 2 Oct 2026
- 12PubMed search: semaglutide[tiab] AND (rheumatoid[tiab] OR "psoriatic"[tiab] OR "inflammation"[ti] OR "C-reactive"[ti]) (60 results)PubMed · 2026pubmed.ncbi.nlm.nih.govAccessed 2 Oct 2026
- 13PubMed search: semaglutide[ti] AND ("knee osteoarthritis" OR "osteoarthritis" OR "obesity-related") AND (pain OR knee) (17 results)PubMed · 2026pubmed.ncbi.nlm.nih.govAccessed 2 Oct 2026
- 14PubMed search: semaglutide[tiab] AND (Alzheimer*[tiab] OR evoke[tiab]) AND (randomized controlled trial[pt] OR clinical trial[pt]) (3 results)PubMed · 2026pubmed.ncbi.nlm.nih.govAccessed 2 Oct 2026
- 15Official web pageOfficial web page · web page
- 16Effect of glucagon-like peptide-1 receptor agonists and co-agonists on body composition: Systematic review and network meta-analysis.Metabolism: clinical and experimental · 2025PMID 39719170Accessed 2 Oct 2026
- 17Retatrutide, a GIP, GLP-1 and glucagon receptor agonist, for people with type 2 diabetes: a randomised, double-blind, placebo and active-controlled, parallel-group, phase 2 trial conducted in the USA.Lancet (London, England) · 2023PMID 37385280Accessed 2 Oct 2026
- 18Two years of replacement therapy in adults with growth hormone deficiency.Clinical endocrinology · 1997PMID 9404448Accessed 2 Oct 2026
- 19WEGOVY prescribing information (FDA label)FDA label, DailyMed · current labeldailymed.nlm.nih.govAccessed 2 Oct 2026
Found an error? Report a correction.